Wockhardt Ltd (WOCKPHARMA) is currently trading at 1,871.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Wockhardt Limited is a global research-driven pharmaceutical and biotechnology company focused on three pillars: a core pharmaceuticals business (~75% of revenue), a diabetes biosimilars/biotech vertical, and a novel antibiotics franchise built from in-house R&D and multiple manufacturing sites across India, Europe and Ireland operating 11 manufacturing facilities and two R&D centres. A decisive inflection: Wockhardt became the first Indian company with an Indian research product (Zaynich) approved by the US FDA, and management projects Zaynich global peak sales of $1.5–2.0 billion while concurrently launching in India and planning Europe and emerging market rollouts. Financial turnaround and margin recovery are notable: FY top line of INR3,373 crore, EBITDA of INR630 crore (about 51% year-on-year growth), PBT INR238 crore, cash equivalents INR662 crore and net debt-to-equity ~0.1, reflecting a multi-year focus on liquidity, deleveraging and profitability. Biosimilars and specialty growth are real: the diabetes biosimilar vertical grew strongly (management cited ~27% biotech growth and emerging markets growth at ~35%), with insulin production scaled 2x and multiple diabetes biosimilar assets in the pipeline, supporting a medium-term doubling of that business. Commercial strategy is distinct: Wockhardt is pursuing a parallel launch playbook for Zaynich — simultaneous US approval commercialization, India access-first pricing and targeted emerging market launches — supported by a newly hired US commercial leadership team and outsourced logistics/3PL partners to accelerate hospital penetration and HEOR evidence generation.

Over the past 52 weeks, Wockhardt Ltd has traded between a low of ₹1,086.80 and a high of ₹2,420.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Wockhardt Ltd has a market capitalization of approximately 31,225.90. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Wockhardt Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 78.27 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 31,225.90 Cr, Wockhardt Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Wockhardt Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Wockhardt Ltd is 78.27. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Wockhardt’s upcoming earnings date is August 10, 2026, when the board is scheduled to consider Q1 FY 2026-27 unaudited results.

Wockhardt’s upcoming earnings date is August 10, 2026, for Q1 FY2026-27.

The issue price was ₹1,105 per share, which was a 4.93% discount to the floor price of ₹1,162.25 per share.

Zaynich is Wockhardt’s novel injectable antibiotic for severe drug-resistant infections, and it received US FDA approval on May 29.